XANAP: A real‐world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia

XANAP: A real‐world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia

Abstract Background ROCKET AF and its East Asian subanalysis demonstrated that rivaroxaban was non‐inferior to warfarin for stroke/systemic embolism (SE) prevention in patients with non‐valvular atrial fibrillation (NVAF), with a favorable benefit–risk profile. XANAP investigated the safety and effe...

Full description

Bibliographic Details
Main Authors: Young‐Hoon Kim, Jaemin Shim, Chia‐Ti Tsai, Chun‐Chieh Wang, Gilbert Vilela, Sombat Muengtaweepongsa, Mohammad Kurniawan, Oteh Maskon, Hsu Li Fern, Thang Huy Nguyen, Thititat Thanachartwet, Kenneth Sim, A. John Camm, the XANAP investigators
Format: Article
Language:English
Published: Wiley 2018-08-01
Series:Journal of Arrhythmia
Subjects:
Asia‐Pacific
bleeding risk
real world
rivaroxaban
stroke prevention
Online Access:https://doi.org/10.1002/joa3.12073

Internet

https://doi.org/10.1002/joa3.12073

Similar Items